Advertisement

Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs

  • Tony K. L. Kiang
  • Kyle John Wilby
  • Mary H. H. Ensom

Table of contents

  1. Front Matter
    Pages i-vii
  2. Kyle John Wilby, Tony K. L. Kiang, Mary H. H. Ensom
    Pages 1-7
  3. Kyle John Wilby, Tony K. L. Kiang, Mary H. H. Ensom
    Pages 9-13
  4. Kyle John Wilby, Tony K. L. Kiang, Mary H. H. Ensom
    Pages 15-25
  5. Tony K. L. Kiang, Kyle John Wilby, Mary H. H. Ensom
    Pages 27-41
  6. Tony K. L. Kiang, Kyle John Wilby, Mary H. H. Ensom
    Pages 79-120
  7. Kyle John Wilby, Tony K. L. Kiang, Mary H. H. Ensom
    Pages 121-131
  8. Tony K. L. Kiang, Kyle John Wilby, Mary H. H. Ensom
    Pages 133-135

About this book

Introduction

Clinically-focussed, with easily accessible tables and chapter summaries suitable for clinicians and researchers,  this comprehensive book provides a systematic, critical evaluation of the current literature. An updated clinical decision-making algorithm specifically tailored to the antiretroviral drugs is also provided. The identified interactions are interpreted in the context of known mechanisms derived from clinical, preclinical, and in vitro data. The clinical relevance of the interactions is systematically evaluated and gaps in literature discussed in the context of potential future experiments. In addition to the comprehensive summary of pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antiretroviral drugs on the market today (i.e. nucleotide reverse-transcriptase inhibitors, non-nucleoside reverse-transcriptase inhibitors, integrase inhibitors, and protease inhibitors), this book also provides detailed section summaries on the epidemiology of HIV infection, diagnosis and pharmacotherapy, basic pharmacology of the individual antiretrovirals, pertinent pre-clinical and in vitro molecular pharmacology, and in vitro drug interaction data available in the literature today. 

Keywords

Nucleotide reverse-transcriptase inhibitors Non-nucleoside reverse-transcriptase inhibitors Integrase inhibitors Protease inhibitors Co-morbidities Polypharmacy Mechanisms

Editors and affiliations

  • Tony K. L. Kiang
    • 1
  • Kyle John Wilby
    • 2
  • Mary H. H. Ensom
    • 3
  1. 1.Faculty of Pharmaceutical SciencesThe University of British ColumbiaVancouverCanada
  2. 2.College of PharmacyQatar UniversityDohaQatar
  3. 3.Faculty of Pharmaceutical SciencesThe University of British ColumbiaVancouverCanada

Bibliographic information

Industry Sectors
Pharma
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods